We are excited to announce that CLSA is now offering its members a program through Illumina for gene sequencing solutions that can offer substantial savings to first time Illumina customers. Illumina technology is responsible for generating more than 90% of the world’s sequencing data. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. This savings program, through BIO Business Solutions®, is the result of collaboration between CLSA and the Biotechnology Innovation Organization (BIO), the world’s largest biotechnology trade association.
Member companies can realize the following benefits of the Illumina program:
- Exclusive rebates on the following benchtop sequencing instrumentation for first-time Illumina customers
|MiSeq®||Allows small genome sequencing and assembly, and enables detection of targeted variants with unmatched accuracy|
|MiSeqDx®||First FDA cleared IVD platform with a growing menu of assays that enables clinical laboratories to create and deploy NGS based molecular diagnostic testing in their labs|
|MiSeq FGx™||A compact, fully validated NGS platform for forensic genomics applications|
|MiniSeq™||Flexible and affordable system that allows researchers to transition easily between sequencing projects for both DNA and RNA|
|NextSeq®500||Enables rapid sequencing of exomes, targeted panels, and transcriptions|
|NextSeq®550||Enables NGS and Cytogenetic Array Scanning on one instrument|
For Research Use Only. Not for use in diagnostic procedures.
For more information about the program and a full list of benefits, please visit http://bbs.bio.org/content/illumina